N/A
N=393
Smoking Prevention Through Social Connections Among Adolescents - ASPIRE
Tobacco Use Behavior
Bottom Line
View on ClinicalTrials.gov: NCT02703597 ↗Enrolled (actual)
393
Serious AEs
0.0%
Results posted
Oct 2024
Primary outcome: Primary: Susceptibility to Vaping — 66; 118 Participants — p=0.80
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Surveys (Behavioral); ASPIRE (Behavioral); GSA-ASPIRE-Network (Behavioral)
- Age
- Pediatric, Adult · 11+ yrs
- Sex
- All
- Sponsor
- University of Florida
- Primary completion
- Mar 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Susceptibility to Vaping |
66; 118 | 0.80 |
| PRIMARY Susceptibility to Using Conventional Tobacco |
63; 106 | 0.70 |
Summary
The central hypothesis of this study is that the addition of social influence strategies to a web-based program called ASPIRE will boost its success in lowering intention to use tobacco among adolescents and experiencing stronger positive social influence. The study will involve a nested group randomized controlled trial with adolescents from after-school programs and schools (e.g., the PK Yonge school) in Florida.
Eligibility Criteria
Inclusion Criteria
- All participants must be of ages 11 through 18 (11 and 18 included; age group for adolescents adopted by several National Institutes of Health)
- Are members of after school program or school
- All participants will be English speaking
- Adolescents with developmental disability, mental or physical, are not excluded from the study. However, they will only be able to participate if (1) they understand the information presented to them in the consent document, and (2) they believe they are capable to engage in the board game, use the internet, and answer survey questions.
- Pregnant adolescents will be eligible to participate in the research study as requested by the NIH based on 2 principles that will be discussed at time of consent.
Exclusion Criteria
-When participants don't meet the inclusion criteria
Data sourced from ClinicalTrials.gov (NCT02703597). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.